retatrutide triple agonist glp-1 gip glucagon receptor Phase 3: 28.7% Weight Loss (2026) Retatrutide for Obesity: Phase 2

While the overall risk remains relatively low, the association has raised alarms among healthcare professionals and regulatory agencies

These questions matter because obesity is a chronic metabolic condition, not a short-term willpower problem

Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA (2001) Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats

Timeline comparison: when results appear The dosage chart dictates your schedule

it represents the body approaching a new set point where energy intake and expenditure reach equilibrium

However in that same video, Dr